First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Bobo Zheng
Xin Wang
Mingtian Wei
Quan Wang
Jiang Li
Liang Bi
Xiangbing Deng
Ziqiang Wang
机构：
[1] Sichuan University,Department of Gastrointestinal Surgery, West China Hospital
[2] First Affiliated Hospital of Xi’an Jiaotong University,Department of Gastroenterology
[3] The Fourth Military Medical University,Digestive disease hospital, Xijing Hospital
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,National Cancer Center/Cancer Hospital
来源：
BMC Cancer | / 19卷
关键词：
First line; Cetuximab; Bevacizumab; Wild type; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
    Shousheng Liu
    Chang Jiang
    Lin Yang
    Jinsheng Huang
    Roujun Peng
    Xiaopai Wang
    Wenzhuo He
    Long Bai
    Yixin Zhou
    Bei Zhang
    Liangping Xia
    Scientific Reports, 10
  • [22] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [23] Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease
    Rivera, F.
    Peeters, M.
    Douillard, J-Y.
    Taieb, J.
    Koukakis, R.
    Demonty, G.
    Siena, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY TRIALS IN FIRST-LINE RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Jarrett, J.
    Weijers, L.
    Hnoosh, A.
    Harty, G.
    von Hohnhorst, P.
    VALUE IN HEALTH, 2014, 17 (07) : A617 - A617
  • [25] Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
    Jiang, Wei
    Yu, Qitao
    Ning, Ruiling
    Zhao, Wenhua
    Wei, Changyuan
    ONCOTARGETS AND THERAPY, 2018, 11 : 4271 - 4281
  • [26] A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF PANITUMUMAB WITH CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER (MCRC) WITH LEFT-SIDED TUMORS
    Zhou, A.
    Cameron, C.
    Mak, D.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
  • [27] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [28] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [29] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [30] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
12345